This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Adverse Effects  • Alert me on articles by topic

Bridget M. Kuehn

JAMA. 2008;300(8):891.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The Food and Drug Administration (FDA) is requiring labeling for fluoroquinolone antibiotics to include a black box warning that patients taking these drugs are at increased risk of tendinitis and tendon rupture.

Despite an existing warning that fluoroquinolones may increase the risk of tendon rupture, a recent FDA analysis revealed that the agency continues to receive many reports of tendon-related adverse events among patients taking these drugs. In addition to the black box warning, the manufacturers of fluoroquinolones are being required to provide medication guides outlining the risk.

Fluoroquinolones increase the risk of tendinitis and tendon rupture in some patients. (Photo credit: Philip Marazzi, MD/www.sciencesource.com)

Individuals older than 60 years, those taking corticosteroids, and individuals who have received kidney, heart, and lung transplants are at greatest risk of developing tendinitis or having a tendon rupture while taking these medications, according to the FDA. Patients who . . . [Full Text of this Article]